Stock SAGE SAGE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Market Closed - Nasdaq
Other stock markets
 04:00:04 2024-04-23 pm EDT 		5-day change 1st Jan Change
12.94 USD +0.39% Intraday chart for Sage Therapeutics, Inc. -17.21% -40.29%
Apr. 18 TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating MT
Apr. 18 Scotiabank Cuts Price Target on Sage Therapeutics to $19 From $34, Maintains Sector Outperform Rating MT

Evolution of the average Target Price on Sage Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d2abe91d6a8a.q1fdrSVRs7aMywzQq7nEfwiOIz7ILRT6qvNofwFgbYY.nWG14G8158f-hGOy3MmiMjn9e1L4WEyl48YKLmcHB9LnNK3yRxP98P6ROA~1ee6bb7b95af7cad3ff0a859b3f86d84

Analyst Recommendations on Sage Therapeutics, Inc.

TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating MT
Scotiabank Cuts Price Target on Sage Therapeutics to $19 From $34, Maintains Sector Outperform Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $17 From $25, Maintains Perform Rating MT
BofA Securities Downgrades Sage Therapeutics to Underperform From Neutral, Adjusts Price Target to $14 From $24 MT
JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating MT
Deutsche Bank Adjust Sage Therapeutics Price Target to $18 From $21, Maintains Hold Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating MT
RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk MT
Wedbush Adjusts Sage Therapeutics' Price Target to $24 From $22, Keeps Neutral Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $23 From $20, Maintains Perform Rating MT
Stifel Cuts Price Target on Sage Therapeutics to $20 From $22, Maintains Hold Rating MT
Deutsche Bank Initiates Coverage on Sage Therapeutics With Hold Rating, $21 Price Target MT
RBC Trims Price Target on Sage Therapeutics to $21 From $22, Keeps Sector Perform, Speculative Risk MT
Wedbush Lifts Sage Therapeutics' PT to $22 From $21, Says Zurzuvae Pricing In-Line With Expectations; Maintains Neutral Rating MT
Goldman Sachs Adjusts Price Target on Sage Therapeutics to $25 From $22, Maintains Neutral Rating MT
RBC Trims Price Target on Sage Therapeutics to $22 From $25, Reflecting Company's Recent Cost Cuts, Keeps Sector Perform Rating MT
Morgan Stanley Adjusts Price Target on Sage Therapeutics to $20 From $49, Maintains Equal-Weight Rating MT
Truist Adjusts Sage Therapeutics' Price Target to $20 From $40, Keeps Hold Rating MT
Goldman Sachs Downgrades Sage Therapeutics to Neutral From Buy, Price Target is $22 MT
Mizuho Adjusts Price Target on Sage Therapeutics to $19 From $45, Maintains Neutral Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $20 From $24, Maintains Perform Rating MT
HC Wainwright Adjusts Price Target on Sage Therapeutics to $27 From $50, Keeps Neutral Rating MT
Needham Downgrades Sage Therapeutics to Hold From Buy MT
Canaccord Genuity Downgrades Sage Therapeutics to Hold From Buy, Cuts Price Target to $21 From $64 MT
Wedbush Trims Sage Therapeutics' PT to $21 From $22, Says Uncertainty Surrounding Zurzuvae to Keep Overhang on Shares; Keeps Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
12.95 USD
Average target price
24.39 USD
Spread / Average Target
+88.33%
High Price Target
70 USD
Spread / Highest target
+440.54%
Low Price Target
14 USD
Spread / Lowest Target
+8.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sage Therapeutics, Inc.

TD Cowen
Scotiabank
Oppenheimer
BofA Securities
JPMorgan Chase
Deutsche Bank Securities
RBC Capital Markets
Wedbush
Stifel Nicolaus
Goldman Sachs
Morgan Stanley
Truist Securities
Mizuho Securities
HC Wainwright
Needham & Co.
Canaccord Genuity
Jefferies & Co.
SVB Securities LLC
Guggenheim
BMO Capital
Loop Capital
Citigroup
Berenberg Bank
SVB Leerink
Cowen
William Blair & Co.
Piper Sandler
Raymond James

Ratings for Sage Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SAGE Stock
  4. Consensus Sage Therapeutics, Inc.